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Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is 
attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itors (TKI) is an effective first line drug for advanced non-small cell lung cancer patients who har-
bor activating EGFR mutation. During the course of treatment, resistance against TKI arises 
which can be contributed to EGFR T790M mutation in about 50–60% of patients. Third genera-
tion TKI may overcome the resistance. In patients who cannot undergo tissue biopsy due to vari-
able reasons, liquid biopsy is an excellent alternative for the detection of EGFR T790M mutation. 
However, this relatively novel method requires standardization and vigorous quality insurance. 
Thus, a standard set of guideline recommendations for liquid biopsy for EGFR mutation testing 
suitable for the Korean medical community is necessary. In this article, we propose a set of provi-
sional guideline recommendations that was discussed and approved by the Cardiopulmonary 
Pathology Study Group of the Korean Society of Pathologists.
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After the discovery of activating epidermal growth factor recep-
tor (EGFR) gene mutation, EGFR tyrosine kinase inhibitors (TKI) 
became the first line of treatment in advanced non-small cell lung 
cancer (NSCLC) with mutated EGFR.1-3 These EGFR TKIs 
such as gefitinib, erlotinib, and afatinib show consistently better 
response rate and prolonged progression-free survival in EGFR 
mutant NSCLC patients.1-3 However, most patients receiving 
EGFR TKI treatment may develop acquired resistance.4-6 Al-
though various mechanisms are involved in this resistance, second-
ary T790M mutation of EGFR gene illustrates 50%–60% of the 
resistance.7,8 A recently developed third generation TKIs can effec-
tively target T790M, and so it is very critical to detect this muta-
tion in patients who has developed acquired resistance against 
first- or second-line EGFR TKIs.9-11
Liquid biopsy is an emerging tool that detects genetic changes 
in circulating tumor DNA (ctDNA) shed from the tumor cells.12-14 
Recently, Cobas EGFR mutation test V2 (Roche, Indianapolis, 
IN, USA) has been approved by Food and Drug Administration 
(FDA) for the detection of EGFR mutations from the blood of 
NSCLC patients.15 Although this non-invasive technique is fasci-
nating and promising, it is still a developing method which needs 
further improvements. Hence, it is necessary to have guidelines 
for its usage. Korean cardiopulmonary study group has prepared 
the first guideline of EGFR mutation detection in blood for clini-
cians and pathologists who actively take part in the diagnosis and 
treatment of lung cancer.
PATIENT ELIGIBILITY
Liquid biopsy for the detection of EGFR mutation can play 
many roles in cancer diagnostics.12-14,16,17 Patients diagnosed with 
lung adenocarcinoma harboring EGFR mutation will be the first 
candidates when they develop resistance against first-line TKIs. 
Especially, when the tumor is too small or located in a challenging 
region to be sampled, liquid biopsy can be a good alternative.14-18 
Patients with poor performance status can also benefit from this 
technique. 
SAMPLE COLLECTION
Sample collection and processing is a critical step in liquid biopsy. 
Since ctDNA is rapidly degraded by the nuclease in blood and 
contaminated by genomic DNA from blood cells, it is essential 
to separate plasma from the sample.13,14 The routine venipunc-
ture technique will be sufficient to collect blood from the patients. 
The sample collection tube should be chosen considering each 
institution’s setting. Conventional ethyldiaminetetraaceticacid 
(EDTA) tube can be used if the samples are processed without 
delay.19,20 Recently, specialized tubes for delaying degradation of 
ctDNA are commercially available.19,20 The tube from Streck 
(Omaha, NE, USA) has been the most widely used collection tube. 
Roche diagnostics and Qiagen have also marketed specialized 
tubes. According to a study,19 conventional EDTA tube and Streck 
tube do not show much difference in their performance when 
samples are processed within 6 hours. When incubated longer 
in EDTA tube, cell-free DNA may be released from the blood cells, 
and EDTA will hinder the polymerase chain reaction (PCR).20 
Tubes from Roche and Qiagen showed similar performance, and 
they are slightly better than Streck tube.20 Specialized tubes can 
sustain sample quality for several days at room temperature before 
processing further (Table 1). 
CIRCULATING TUMOR DNA ISOLATION
Before ctDNA extraction, blood should be processed into 
plasma through double centrifugation. Plasma samples are better 
than serum samples, which can be contaminated by DNA released 
from immune cells.13 Since a small amount of ctDNA is present in 
plasma, isolation is a critical step in the process for saving tumor 
DNA. Several commercial kits for isolation are available in the 
market (Table 2).21,22 These are manual, semiautomatic, and fully 
Table 1. Comparison of specialized tubes for collection of ctDNA
Company    Trade name Volume (mL) Temperature (°C) Storage duration (day)
Streck cfDNA BCT 10 6–37 14 
Roche Cell-Free DNA Collection Tube 8.5 18–25 7 
Qiagen PAXgene Blood ccfDNA Tube 10 18–25 7 
ctDNA, circulating tumor DNA.
Table 2. Commercially available ctDNA extraction kits
Company Trade name Method Automation
ThermoFisher    MagMAX    Magnetic beads        Semiauto
Promega    Maxwell RSC    Magnetic beads        Semiauto
Roche    Cobas    Silica membrane        Manual
Qiagen    QIAamp    Silica membrane        Semiauto
ctDNA, circulating tumor DNA.
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automatic. Manual protocol uses column-based method while 
semi-automatic instrument works with magnetic beads. Previous 
studies showed variable results depending on the extraction kits, 
though they all had similar performances.21,22 The technician’s 
skill and protocol optimization may be one of the critical factors 
for yielding better ctDNA. Table 1 summarizes commercial 
ctDNA extraction kits. 
MUTATION DETECTION METHODS
High sensitivity detection methods are required to detect 
EGFR mutations from liquid samples. Kits for detecting muta-
tions have been developed and are commercially available.23-25 
Each kit requires different quality and amount of DNA (Table 
3). They depend on real time PCR technology with their own 
variations. Roche Cobas uses real time PCR with Taqman like 
probe and Qiagen has released ARMS based kits, Therascreen 
EGFR RGQ. Another PCR based technique uses peptide nucleic 
acid clamping and Panamutyper (Panagene, Daejeon, Korea). 
The Roche and Qiagen systems use their own PCR machine from 
Roche and Qiagen while Panamutyper can run on any qualified 
PCR machines. The number of mutations these kits can detect 
are different; however, together they include exon 19 deletion, 
T790M and L858R. Currently, only Roche kit has acquired 
FDA approval. The most important element of these kits is how 
sensitively and specifically they can detect mutations in liquid 
samples. There are certain studies to evaluate their performance 
and report sensitivities ranging from 62% to 67.5% and speci-
ficities ranging from 88% to 97%.26-29 In the ASSESS study, 
these three kits showed high specificity, however, sensitivity was 
equal to or less than 75%.25 For T790M, sensitivity was 41% 
and 29% for Cobas and Therascreen, respectively, and specificity 
was 100% for both kits from the patients enrolled in AURA 
trial.10 Therefore, deciding the best kit will depend on the labo-
ratory’s choice with consideration of their requirements. Features 
of these products are summarized in Table 3. Other platforms 
using digital PCR and next generation sequencing are still far 
from widespread use in clinical setting.24 
REPORTING FORMAT
Once liquid biopsy for detecting T790M mutation is done, 
the reports should contain the following information: pathologic 
number, age, sex, hospital unit number, sample source, requesting 
physician, requesting department, adequacy for testing (amount 
of DNA extracted), receipt day, report day, storage tube, meth-
odology used, exons tested and associated range of detectable 
mutations, mutation status, comments, testing technician, and 
corresponding pathologist. Since the patients already have sensi-
tizing EGFR mutation, it is recommended to include the type 
of original EGFR alteration and previous histologic diagnosis. 
PROPOSAL FOR AN EXTERNAL QUALITY 
ASSESSMENT PROGRAM
Since liquid biopsy technique has not been validated yet, vigor-
ous quality assurance is necessary. Although there is no recom-
mended program for external quality assessment (EQA), one 
pilot trial for EGFR testing in blood is ongoing in Germany.30 
Another program for BRAF and KRAS is also being conducted.31 
Since patient derived standard sample is difficult to store and 
distribute, artificial sample mimicking the real one can be used 
instead.30,31 We are in the process of developing Korean EQA 
program.
ROLE OF PATHOLOGISTS
Performance and interpretation of liquid biopsy require broad 
knowledge in lung cancer pathology. Pathologists have an impor-
tant role in the diagnosis and management of cancer and thus can 
interpret liquid biopsy results in conjunction with the histologic 
diagnosis, previous status of EGFR-activating mutation, and 
clinical situation. The liquid biopsy in lung cancer is usually per-
formed in patients whose previous EGFR mutation status has been 
known. The sole purpose of this technique is to detect a T790M 
mutation responsible for TKI resistance. Unlike tissue specimens, 
in which the pathologists can determine the percentage of tumor 
Table 3. EGFR mutation detection kits in plasma
Company Trade Name Method Detectable mutations
Roche         Cobas        Real time PCR        EX19Del, S768I, T790M, L858R, L861Q, G719X, EX20Ins
Qiagen         Therascreen RGQ        ARMS        Ex19Del, T790M, L858R
Panagene         Mutyper        PNA clamp        EX19Del, S768I, T790M, L858R, L861Q, G719X, EX20Ins
Bio-Rad         rimePCR ddPCR Mutation Assay        Digital PCR        Ex19Del, T790M, L858R, L861Q
Sysmex-Inostics         OncoBEAM        Digital PCR        Ex19Del, T790M, L858R, C797S
EGFR, epidermal growth factor receptor; PCR, polymerase chain reaction; PNA, peptide nucleic acid.
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lung cancer including diagnosis, treatment, and prognosis. How-
ever, in debatable cases, discussion between pathologists, physi-
cians, and radiologists is critical. This method will soon play a ma-
jor role in early diagnosis, monitoring of treatment, and detection 
of minimal residual disease. Currently, it cannot replace the con-
ventional pretreatment tissue diagnosis.14 It is important to val-
idate and improve the performance of this technique before it 
is widely used in clinical practice. Liquid biopsy performed in 
EGFR has provided a platform for determining gene mutations 
in KRAS, ALK, PI3CA, and BRAF as well.
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cells, it is extremely difficult to estimate whether the blood sam-
ple contains a sufficient amount of tumor DNA. If the sample is 
adequate, the test generally finds the original EGFR-activating 
mutation, which may act as an internal control for the presence of 
ctDNA.13 When it has not detected any EGFR-activating mu-
tation including previously existing one or reported mutations 
other than the preexisting ones or T790M, pathologists should be 
able to interpret the result. In the former, test should be repeated 
because the samples might have been degraded and contain insuf-
ficient ctDNA. In the latter, the newly emerged mutation, in the 
presence of newly developed lesion, may indicate a metachronous 
primary tumor. The communication between pathologists, clini-
cians, and radiologists is important for further diagnosis and 
management of cancer. Moreover, lung adenocarcinoma under-
goes frequent transformation into small cell carcinoma when it is 
treated with TKI, while maintaining the original EGFR muta-
tion.7,8,32 Recommended interpretation is suggested in Table 4. 
PERSPECTIVES AND ADDITIONAL 
RECOMMENDATIONS
EGFR mutation testing performed with blood or other liquid 
sample is a non-invasive method, which can be more widely ad-
opted. Laboratories must get familiar with liquid samples and 
develop their own protocols to handle these specimens. They 
can choose appropriate sample tubes, extraction kits, detection 
methods, and other instruments. They should select the most suit-
able combination in accordance with their requirements, unless 
the detection kits indicate specific methods and instruments.31 
Although sensitivity of tissue biopsy is higher than liquid biopsy, 
both are far from perfection and T790M mutation can be de-
tected only in one of the two methods. Reportedly, allele frac-
tion of T790M mutation tends to correlate with treatment effi-
cacy of osimertinib.33 Therefore, absence of T790M in tumor 
tissue while it is detected in plasma might reflect low allele fre-
quency and lead to poor response. Therefore, the two methods 
are complementary to each other and should be selected accord-
ing to each patient’s condition (Fig. 1).
CONCLUSIONS
Liquid biopsy is a promising method, which is safe and con-
venient. Before more experiences and data are accumulated, liquid 
biopsy should be performed with great caution. There are a few 
steps in liquid biopsy, which can produce false negative or false 
positive results. Interpretation requires profound knowledge of 
Fig. 1. Proposed diagnostic algorithm for the detection of epider-
mal growth factor receptor (EGFR) T790M mutation. NSCLC, non-
small cell lung cancer; TKI, tyrosine kinase inhibitor; CTx, chemo-
therapy.
Table 4. Recommended interpretation of EGFR mutation test from 
blood
Sensitizing 
  mutation
T790M Interpretation
Detected    Detected T790M positive: start treatment with 
third generation TKI 
Detected    Not detected T790M negative: tissue biopsy 
recommended 
Not detected    Detected T790M positive: confirmation is 
necessary 
Not detected    Not detected Non-informative: tissue biopsy strongly 
recommended 
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
TKI treatment for EGFR mutant NSCLC
Resistance
3rd generation TKI
New lesion in lung, 
transformation
Liquid biopsy for 
detection of T790M
Tissue biopsy 
with EGFR testing
Tissue biopsy for 
detection of T790M
Negative
Negative
CTx
Positive
Positive
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